Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-Cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05890352

Title field or adapter rule

{'original_value': 'Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-Cell Lymphoma', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-11-01T01:03:15.737867+00:00

Published At

2026-10-28T00:00:00+00:00

Record Updated At

2026-10-28

Source Retrieved At

2026-11-01T01:03:15.424322+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Grade 3b Follicular Lymphoma", "High Grade B-Cell Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "Recurrent Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Transformed Non-Hodgkin Lymphoma"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-28", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT05890352"

protocolSection.identificationModule.officialTitle

"Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-Cell Lymphoma"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Grade 3b Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• High Grade B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
• Recurrent Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Transformed Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Part I, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part I, Arm III (tafasitamab, lenalidomide, zanubrutinib)', 'Part II, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part II, Arm II (tafasitamab, lenalidomide)', 'Part II, Arm III (tafasitamab, lenalidomide, zanubrutinib)'], 'description': 'Undergo optional collection of blood', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part I, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part I, Arm III (tafasitamab, lenalidomide, zanubrutinib)', 'Part II, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part II, Arm II (tafasitamab, lenalidomide)', 'Part II, Arm III (tafasitamab, lenalidomide, zanubrutinib)'], 'description': 'Undergo PET/CT and CT', 'name': 'Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part I, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part I, Arm III (tafasitamab, lenalidomide, zanubrutinib)', 'Part II, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part II, Arm II (tafasitamab, lenalidomide)', 'Part II, Arm III (tafasitamab, lenalidomide, zanubrutinib)'], 'description': 'Given PO', 'name': 'Lenalidomide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part I, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part I, Arm III (tafasitamab, lenalidomide, zanubrutinib)', 'Part II, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part II, Arm II (tafasitamab, lenalidomide)', 'Part II, Arm III (tafasitamab, lenalidomide, zanubrutinib)'], 'description': 'Undergo MRI', 'name': 'Magnetic Resonance Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part I, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part I, Arm III (tafasitamab, lenalidomide, zanubrutinib)', 'Part II, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part II, Arm II (tafasitamab, lenalidomide)', 'Part II, Arm III (tafasitamab, lenalidomide, zanubrutinib)'], 'description': 'Undergo PET/CT', 'name': 'Positron Emission Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part I, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part I, Arm III (tafasitamab, lenalidomide, zanubrutinib)', 'Part II, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part II, Arm II (tafasitamab, lenalidomide)', 'Part II, Arm III (tafasitamab, lenalidomide, zanubrutinib)'], 'description': 'Ancillary studies', 'name': 'Quality-of-Life Assessment', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part I, Arm III (tafasitamab, lenalidomide, zanubrutinib)', 'Part II, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part II, Arm II (tafasitamab, lenalidomide)', 'Part II, Arm III (tafasitamab, lenalidomide, zanubrutinib)'], 'description': 'Ancillary studies', 'name': 'Questionnaire Administration', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part I, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part I, Arm III (tafasitamab, lenalidomide, zanubrutinib)', 'Part II, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part II, Arm II (tafasitamab, lenalidomide)', 'Part II, Arm III (tafasitamab, lenalidomide, zanubrutinib)'], 'description': 'Given IV', 'name': 'Tafasitamab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part I, Arm I (tafasitamab, lenalidomide, tazemetostat)', 'Part II, Arm I (tafasitamab, lenalidomide, tazemetostat)'], 'description': 'Given PO', 'name': 'Tazemetostat', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Part I, Arm III (tafasitamab, lenalidomide, zanubrutinib)', 'Part II, Arm III (tafasitamab, lenalidomide, zanubrutinib)'], 'description': 'Given PO', 'name': 'Zanubrutinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Lenalidomide (protocolSection.armsInterventionsModule.interventions[].name)
• Tazemetostat (protocolSection.armsInterventionsModule.interventions[].name)
• Zanubrutinib (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.